Achieving Stable Growth in Net Sales and a 20% Ordinary Profit Margin on Net Sales
First written in FY2016. 19 of 42 entries say "Advanced", first in FY2018-Q3. Latest entry: 2026-08-05.
Techno Medica moved to the "Worse" side of this theme in 2016, 5 years before the typical company in this theme (2021).
The whole theme swung hardest in 2024: 12 of 45 companies on the "Worse" side.
11 other companies' latest entry also says "Advanced".
- FY2026ReframedAnnual report
「This fiscal year is the final year of the current medium-term management plan, and the numerical targets were achieved based on the three-year results.」
The three-year cumulative results under the 2023 Medium-Term Management Plan were revenue of ¥31,420 million, operating profit of ¥4,800 million and a cumulative operating margin of 15.3%, exceeding the plan targets of revenue of ¥30,800 million and operating profit of ¥4,500 million. Meanwhile, the 2026 Medium-Term Management Plan has been updated to target revenue of ¥32,100 million, operating profit of ¥3,770 million and ROE of 5.5%, 6.1% and 7.7% for the fiscal years ending March 2027 through March 2029, respectively. - FY2026-H1WorsenedAnnual report
「As a result, revenue for the interim accounting period was ¥4,104.407 million, down 0.3% year on year. Revenue was also slightly below the level of the same period of the previous fiscal year, as sales of blood collection tube preparation equipment and systems in the domestic market fell below the previous-year level. In terms of profit, gross profit declined 5.9% year on year to ¥1,956.894 million in line with the decrease in revenue. Selling, general and administrative expenses declined 4.7% year on year to ¥1,690.402 million, mainly because R&D expenses were below the previous-year level. Operating profit was ¥266.491 million, down 12.6% year on year, and ordinary profit was ¥294.334 million, down 1.4%.」
Interim revenue declined 0.3% year on year, operating profit fell 12.6%, and ordinary profit fell 1.4%. The ordinary profit margin on revenue was also approximately 7.2%, below the previous 20% target. - FY2025WorsenedAnnual report
「The three-year cumulative targets were revenue of ¥30,800 million and operating profit of ¥4,500 million. Although the fiscal year ending March 2025 fell short of plan, the two-year cumulative results through the fiscal year ending March 2025 exceeded the management indicators of the 2023 Medium-Term Management Plan.」
For the fiscal year ending March 2025, revenue was ¥9,900 million and operating profit was ¥1,300 million, below the plan of revenue of ¥10,000 million and operating profit of ¥1,400 million. The company also stated that the two-year cumulative results exceeded plan. - FY2025-H1WorsenedAnnual report
「In terms of profit, gross profit increased 0.8% year on year to ¥2,078.530 million in line with the increase in revenue. Selling, general and administrative expenses increased 15.4% year on year to ¥1,773.727 million, mainly due to higher R&D expenses and personnel expenses related to blood collection tube preparation equipment and systems. Operating profit was ¥304.802 million, down 41.8% year on year, ordinary profit was ¥298.581 million, down 44.0%, and interim net income was ¥221.846 million, down 41.1%.」
While revenue for the interim period increased 1.5% year on year, operating profit fell 41.8% and ordinary profit fell 44.0%. Profit performance has deteriorated relative to revenue growth. - FY2024AchievedAnnual report
「For the fiscal year ending March 2024, the company achieved the management targets of the 2023 Medium-Term Management Plan. Management indicators: fiscal year ending March 2024—plan, actual, plan achievement; revenue—¥9,800 million, ¥10,280 million, 104.9%; operating profit—¥1,300 million, ¥1,840 million, 141.6%; operating margin—13.3%, 17.9%, 134.9%.」
For the fiscal year ending March 2024 targets under the 2023 Medium-Term Management Plan, revenue was ¥10,280 million against a target of ¥9,800 million, operating profit was ¥1,840 million against ¥1,300 million, and operating margin was 17.9% against 13.3%, with the company explicitly stating that the management targets were achieved. - FY2024-Q3AdvancedAnnual report
「As a result, revenue for the cumulative third quarter was ¥6,424.175 million, up 6.0% year on year. Sales projects for blood collection tube preparation equipment and systems continued to progress steadily, mainly in the domestic market, while sales of specimen testing equipment and consumables also grew. In terms of profit, gross profit increased 7.6% year on year to ¥3,228.995 million. Selling, general and administrative expenses increased 5.7% year on year to ¥2,300.961 million, due mainly to wage increases and higher training expenses as part of human capital investment, investment to establish the foundation of the R&D structure under the investment plan, and higher costs associated with systemization of operations. Operating profit was ¥928.034 million, up 12.6% year on year, ordinary profit was ¥937.863 million, up 13.0%, and net income for the quarter was ¥646.374 million, up 14.6%.」
For the cumulative third quarter, revenue increased 6.0% year on year, operating profit increased 12.6%, and ordinary profit increased 13.0%, maintaining the trend of higher revenue and profit seen through the previous quarter. Growth in domestic sales of blood collection tube preparation equipment and systems, specimen testing equipment and consumables was cited as a factor. - FY2024-Q2AdvancedAnnual report
「As a result, revenue for the cumulative second quarter was ¥4,056.387 million, up 7.5% year on year. Sales projects for blood collection tube preparation equipment and systems progressed steadily, mainly in the domestic market, while sales of specimen testing equipment and consumables also remained firm. In terms of profit, gross profit increased 9.9% year on year to ¥2,061.040 million. Selling, general and administrative expenses increased 7.6% year on year to ¥1,537.466 million, mainly due to higher R&D expenses related to blood collection tube preparation equipment and systems. Operating profit was ¥523.574 million, up 17.3% year on year, ordinary profit was ¥533.177 million, up 17.2%, and net income for the quarter was ¥376.912 million, up 21.9%.」
For the cumulative second quarter, revenue increased 7.5% year on year, operating profit increased 17.3%, and ordinary profit increased 17.2%, improving from the lower revenue and profit in FY2024-Q1. Domestic sales of blood collection tube preparation equipment and systems, specimen testing equipment and consumables were cited as factors. - FY2024-Q1WorsenedAnnual report
「As a result, revenue for the cumulative first quarter was ¥1,770.498 million, down 0.9% year on year. In terms of profit, gross profit increased 2.9% year on year to ¥869.108 million. Selling, general and administrative expenses increased 9.0% year on year to ¥787.541 million, mainly due to higher R&D expenses related to blood collection tube preparation equipment and systems. Operating profit was ¥81.566 million, down 33.0% year on year, ordinary profit was ¥91.185 million, down 29.6%, and net income for the quarter was ¥72.157 million, down 17.4%.」
In FY2024-Q1, revenue declined 0.9% year on year, operating profit fell 33.0%, and ordinary profit fell 29.6%, indicating deterioration in performance against the revenue growth and profitability targets. - FY2023RaisedAnnual report
「We have formulated a new three-year medium-term management plan beginning in FY2023, or the fiscal year ending March 2024. To achieve sustainable growth, we will strengthen our business foundation, promote proactive R&D investment and pursue further stable growth. Management indicators: fiscal year ending March 2024—revenue ¥9,800.000 million, operating profit ¥1,300.000 million, operating margin 13.3%; fiscal year ending March 2025—revenue ¥10,000.000 million, operating profit ¥1,400.000 million, operating margin 14.0%; fiscal year ending March 2026—revenue ¥11,000.000 million, operating profit ¥1,800.000 million, operating margin 16.4%; three-year total—revenue ¥30,800.000 million, operating profit ¥4,500.000 million, operating margin 14.6%.」
A new 2023 Medium-Term Management Plan was formulated, setting cumulative three-year targets of revenue of ¥30,800.000 million and operating profit of ¥4,500.000 million for the fiscal years ending March 2024 through March 2026. The cumulative revenue and operating profit targets were raised from those under the previous three-year plan. - FY2023-Q3WorsenedAnnual report
「As a result, revenue for the cumulative third quarter was ¥6,061.131 million, down 5.4% year on year. In terms of profit, gross profit declined 4.7% year on year to ¥3,001.724 million in line with the decrease in revenue. Selling, general and administrative expenses were ¥2,177.786 million, up 0.2% year on year. Operating profit was ¥823.937 million, down 15.4% year on year, ordinary profit was ¥829.609 million, down 15.6%, and net income for the quarter was ¥563.860 million, down 16.2%.」
Cumulative third-quarter revenue declined 5.4% year on year and ordinary profit fell 15.6%. Although the rate of revenue decline narrowed from the previous quarter, performance against the growth and profitability targets has continued to deteriorate. - FY2023-Q2WorsenedAnnual report
「As a result, revenue for the cumulative second quarter was ¥3,772.380 million, down 12.1% year on year. In terms of profit, gross profit declined 11.3% year on year to ¥1,875.203 million in line with the decrease in revenue. Selling, general and administrative expenses were ¥1,428.696 million, down 1.0% year on year. Operating profit was ¥446.506 million, down 33.3% year on year, ordinary profit was ¥454.927 million, down 32.7%, and net income for the quarter was ¥309.226 million, down 34.0%.」
Revenue, operating profit, ordinary profit and net income for the quarter were all below the levels of the same period of the previous fiscal year, indicating deterioration in revenue growth and profitability. - FY2023-Q1WorsenedAnnual report
「As a result, revenue for the cumulative first quarter was ¥1,786.155 million, down 11.3% year on year.」
Revenue declined 11.3% year on year, operating profit fell 50.5%, and ordinary profit fell 48.2%. First-quarter performance against the revenue growth and profitability targets has deteriorated. - FY2022AdvancedAnnual report
「For the fiscal year ending March 2022, revenue was ¥9,699.077 million and operating profit was ¥1,861.868 million, both in line with the plan. We will continue working toward the targets under the cumulative three-year medium-term management plan of revenue of ¥29,200.000 million and operating profit of ¥3,500.000 million, both cumulative totals for the three years.」
For the fiscal year ending March 2022, revenue exceeded the plan of ¥9,500.000 million by ¥199.077 million, while operating profit exceeded the plan of ¥1,000.000 million by ¥861.868 million. The cumulative three-year targets remain in place. - FY2022-Q3AdvancedAnnual report
「As a result, revenue for the cumulative third quarter was ¥6,408.817 million, up 9.7% year on year. Sales of blood collection tube preparation equipment and related systems and consumables in the domestic market continued to recover, resulting in revenue above the level of the same period of the previous fiscal year. In terms of profit, gross profit increased 10.7% year on year to ¥3,148.438 million in line with the increase in revenue. Selling, general and administrative expenses were ¥2,174.268 million, up 5.1% year on year. Operating profit was ¥974.169 million, up 25.8% year on year, ordinary profit was ¥983.337 million, up 25.3%, and net income for the quarter was ¥673.151 million, up 22.3%.」
Cumulative third-quarter revenue increased 9.7% year on year, operating profit increased 25.8%, and ordinary profit increased 25.3%, with higher revenue and profit continuing. The recovery in sales of blood collection tube preparation equipment, related systems and consumables was cited as a factor. - FY2022-Q2AdvancedAnnual report
「As a result, revenue for the cumulative second quarter was ¥4,291.044 million, up 15.9% year on year. The recovery trend in sales of the main blood collection tube preparation equipment, related systems and consumables continued, resulting in revenue above the level of the same period of the previous fiscal year. In terms of profit, gross profit increased 19.5% year on year to ¥2,113.456 million in line with the increase in revenue. Selling, general and administrative expenses were ¥1,443.736 million, up 5.8% year on year. Operating profit was ¥669.719 million, up 65.5% year on year, ordinary profit was ¥676.252 million, up 64.0%, and net income for the quarter was ¥468.293 million, up 66.3%.」
Cumulative second-quarter revenue increased 15.9% year on year, operating profit increased 65.5%, and ordinary profit increased 64.0%, moving from lower revenue and profit in the same period of the previous fiscal year to higher revenue and profit. The recovery in sales of the main equipment, related systems and consumables was cited as a factor. - FY2022-Q1AdvancedAnnual report
「As a result, revenue for the cumulative first quarter was ¥2,014.165 million, up 19.9% year on year. Sales of our main blood collection tube preparation equipment and related systems recovered, while sales of consumables and other products also increased steadily, resulting in revenue above the level of the same period of the previous fiscal year. In terms of profit, gross profit increased 24.2% year on year to ¥949.258 million in line with the increase in revenue.」
Revenue increased 19.9% year on year, reflecting a recovery in sales of the main equipment and related systems and an increase in consumables sales. Ordinary profit also increased 196.8% year on year, representing a clear recovery from the decline in revenue and profit in the first quarter of the previous fiscal year. - FY2021AdvancedAnnual report
「We also newly formulated a three-year medium-term management plan beginning in FY2020, or the fiscal year ending March 2021. Actual revenue of ¥9,040.115 million and operating profit of ¥1,607.791 million for the fiscal year ending March 2021 were in line with the plan. We will continue working toward the targets under the cumulative three-year medium-term management plan of revenue of ¥29,200.000 million and operating profit of ¥3,500.000 million, both cumulative totals for the three years.」
For the fiscal year ending March 2021, revenue was ¥159.884 million below the plan of ¥9,200.000 million, while operating profit was ¥607.791 million above the plan of ¥1,000.000 million, and the operating margin was 17.8%. The three-year plan remains in place. - FY2021-Q3WorsenedAnnual report
「Revenue for the cumulative third quarter was ¥5,841.104 million, down 15.5% year on year, although the rate of decline narrowed from the cumulative second quarter. In terms of profit, gross profit declined 9.4% year on year to ¥2,843.035 million in line with the decrease in revenue. Selling, general and administrative expenses declined 9.4% to ¥2,068.825 million due in part to reductions in various expenses amid the COVID-19 pandemic. Operating profit was ¥774.209 million, down 9.6% year on year, ordinary profit was ¥784.647 million, down 8.9%, and net income for the quarter was ¥550.301 million, down 18.0%.」
Cumulative third-quarter revenue, operating profit and ordinary profit were all below the levels of the same period of the previous fiscal year. The ordinary profit margin on revenue was also approximately 13.4%, indicating deterioration against the previous profitability target. - FY2021-Q2WorsenedAnnual report
「As a result, revenue for the cumulative second quarter was ¥3,701.344 million, down 21.3% year on year, despite specimen testing equipment revenue being above the previous-year level, due in part to a lull in replacement demand for blood collection tube preparation equipment and related systems in the domestic market. In terms of profit, gross profit declined 16.7% year on year to ¥1,769.037 million in line with the decrease in revenue. Operating profit was ¥404.669 million, down 33.2% year on year, and ordinary profit was ¥412.451 million, down 32.2%.」
Cumulative second-quarter revenue declined 21.3% year on year, while ordinary profit fell 32.2%. Performance against the stable revenue growth and profitability targets has deteriorated. - FY2021-Q1WorsenedAnnual report
「As a result, revenue for the cumulative first quarter was ¥1,679.835 million, down 23.6% year on year. In terms of profit, gross profit declined 17.5% year on year to ¥764.355 million in line with the decrease in revenue. Selling, general and administrative expenses declined slightly, by 0.5%, to ¥684.336 million. Operating profit was ¥80.018 million, down 66.5% year on year, ordinary profit was ¥84.188 million, down 64.8%, and net income for the quarter was ¥59.014 million, down 74.3%.」
Revenue declined 23.6% year on year, while ordinary profit also fell 64.8%. Performance for the quarter has deteriorated against the previous revenue growth and profitability targets. - FY2020ReframedAnnual report
「Under the 2020 Medium-Term Management Plan, we regard the following as important management indicators. Revenue (¥ thousand) 9,200,000 9,500,000 10,500,000 Operating profit (¥ thousand) 1,000,000 1,000,000 1,500,000 Operating margin (%) 10.9 10.5 14.3」
Under the 2020 Medium-Term Management Plan, the indicators are revenue, operating profit and operating margin for the fiscal years ending March 2021 through March 2023, replacing the previous targets of annual revenue growth of 12.5%–15.0% and a 20% ordinary profit margin on revenue. - FY2020-Q3AdvancedAnnual report
「Amid this operating environment, we steadily responded to large-scale replacement projects for blood collection tube preparation equipment in the domestic market and to steadily expanding demand for consumables, particularly in the domestic market. As a result, revenue for the cumulative third quarter was ¥6,915.845 million, up 12.3% year on year. In terms of profit, gross profit increased 9.5% year on year to ¥3,139.424 million as a result of higher revenue. Selling, general and administrative expenses increased 13.5% year on year to ¥2,283.150 million, mainly due to higher personnel expenses resulting from an increase in staff. Operating profit was ¥856.273 million, up 0.1% year on year, ordinary profit was ¥861.565 million, up 0.4%, and net income for the quarter was ¥671.134 million, up 8.7%.」
Cumulative third-quarter revenue increased 12.3% year on year, maintaining the upward revenue trend following the decline in the same period of the previous fiscal year. The ordinary profit margin on revenue was approximately 12.5%, still below the previous 20% target. - FY2020-Q2AdvancedAnnual report
「Amid this operating environment, we steadily responded to large-scale replacement projects for blood collection tube preparation equipment in the domestic market and to steadily expanding demand for consumables, particularly in the domestic market. As a result, revenue for the cumulative second quarter was ¥4,704.692 million, up 12.9% year on year. In terms of profit, gross profit increased 8.0% year on year to ¥2,122.565 million as a result of higher revenue. Selling, general and administrative expenses increased 16.0% year on year to ¥1,516.740 million, mainly due to higher personnel expenses resulting from an increase in staff. Operating profit was ¥605.825 million, down 7.9% year on year, ordinary profit was ¥607.899 million, down 8.0%, and net income for the quarter was ¥493.726 million, up 3.8%.」
Revenue increased 12.9% year on year, exceeding the lower end of the previous annual growth target of 12.5%–15.0%. However, the ordinary profit margin was approximately 12.9%, below the 20% ordinary profit margin on revenue target. - FY2020-Q1AdvancedAnnual report
「Amid this operating environment, we steadily responded to large-scale replacement projects for blood collection tube preparation equipment in the domestic market and to steadily expanding demand for consumables, particularly in the domestic market. As a result, revenue for the cumulative first quarter was ¥2,197.701 million, up 21.1% year on year.」
First-quarter revenue increased 21.1% year on year, exceeding the previously stated annual growth target of 12.5%–15.0%. However, the ordinary profit margin was approximately 10.9%, still below the 20% ordinary profit margin on revenue target. The response to large-scale replacement projects and consumables demand was cited as a factor behind the revenue increase. - FY2019AdvancedAnnual report
「As a result, revenue for the fiscal year was ¥9,332.420 million, up 7.8% from the previous fiscal year.」
Full-year revenue increased 7.8% from the previous fiscal year, improving from the 2.3% increase in the previous fiscal year. However, it did not reach the previous annual growth target of 12.5%–15.0%, and the ordinary profit margin was approximately 16.5%, below the 20% target. - FY2019-Q3AdvancedAnnual report
「As a result, revenue for the cumulative third quarter was ¥6,158.477 million, up 8.0% year on year. In terms of profit, gross profit increased 6.5% year on year to ¥2,868.117 million as a result of higher revenue. Selling, general and administrative expenses increased 8.8% year on year to ¥2,012.427 million, due mainly to higher personnel expenses and increased shipping costs for consumables and other items. Operating profit was ¥855.690 million, up 1.3% year on year, and ordinary profit was ¥857.757 million, up 1.8%.」
Cumulative third-quarter revenue increased 8.0% year on year and ordinary profit increased 1.8%, resulting in higher revenue and profit than in the same period of the previous fiscal year. This does not state that the previously stated annual revenue growth target of 12.5%–15.0% and 20% ordinary profit margin on revenue have been achieved. - FY2019-Q2AdvancedAnnual report
「Amid this operating environment, we focused on reliably capturing replacement demand and developing new needs while expanding our product lineup, including launching sales of Assist More, the latest system in our blood collection support system lineup, which assists blood collection operations by calling patients and displaying blood collection patient information. In the specimen testing equipment field, we also continued active sales activities centered on our mainstay blood gas analyzers. As a result, revenue for the cumulative second quarter was ¥4,166.390 million, up 22.0% year on year. In terms of profit, gross profit increased 22.7% year on year to ¥1,965.455 million as a result of higher revenue. Selling, general and administrative expenses increased 9.9% year on year to ¥1,307.367 million, mainly due to higher R&D expenses related to blood collection tube preparation equipment and higher personnel expenses resulting from the strengthening of the service structure at locations nationwide. Operating profit was ¥658.088 million, up 59.9%, ordinary profit was ¥660.553 million, up 61.4%, and net income for the quarter was ¥475.438 million, up 22.5%.」
Revenue increased 22.0% year on year and ordinary profit increased 61.4%, representing a clear improvement from the previous period of declining revenue. The ordinary profit margin on revenue was approximately 15.9%, still below the 20% target. - FY2019-Q1WorsenedAnnual report
「As a result, revenue for the cumulative first quarter was ¥1,815.394 million, up 9.3% year on year. In terms of profit, gross profit increased 7.6% year on year to ¥843.865 million as a result of higher revenue. Selling, general and administrative expenses increased 17.4% year on year to ¥670.946 million, mainly due to higher R&D expenses related to the new blood collection tube preparation equipment and higher personnel expenses resulting from the strengthening of the service structure at locations nationwide. Operating profit was ¥172.918 million, down 18.8% year on year, and ordinary profit was ¥175.141 million, down 16.8%.」
While revenue increased 9.3% year on year, ordinary profit declined 16.8%. The revenue increase was below the previous annual target of 12.5%–15.0%, and the ordinary profit margin on revenue was approximately 9.6%, below the 20% target. Performance against the overall targets has therefore deteriorated. - FY2018AdvancedAnnual report
「As a result, revenue for the fiscal year was ¥8,654.247 million, up 2.3% from the previous fiscal year.」
Revenue turned to a 2.3% year-on-year increase, improving from the decline in the previous fiscal year. However, it did not reach the previously stated stable annual growth target of 12.5%–15.0%. - FY2018-Q3AdvancedAnnual report
「Performance for the cumulative third quarter was supported mainly by strong sales of consumables in the domestic market, with revenue reaching ¥5,704.644 million, up 2.1% year on year.」
Cumulative third-quarter revenue turned to a 2.1% year-on-year increase, improving from the decline in the same period of the previous fiscal year. However, it remained below the annual growth target of 12.5%–15.0% set in FY2016. - FY2018-Q2WorsenedAnnual report
「However, due to a year-on-year decline in sales projects for the equipment itself in both Japan and overseas, revenue for the cumulative second quarter was ¥3,414.155 million, down 9.3% year on year.」
Cumulative second-quarter revenue declined 9.3% year on year, and performance against the stable revenue growth target deteriorated. - FY2018-Q1WorsenedAnnual report
「As a result, revenue for the cumulative first quarter was ¥1,660.388 million, down 4.8% year on year.」
Revenue declined 4.8% year on year, while ordinary profit also fell 21.9% year on year. Performance against the stable revenue growth target has deteriorated. - FY2017WorsenedAnnual report
「As a result, revenue for the fiscal year was ¥8,457.238 million, down 6.4% from the previous fiscal year. The proportion of overseas revenue in total revenue increased 1.8 percentage points from the previous fiscal year to 10.6%.」
FY2017 revenue declined 6.4% from the previous fiscal year, while ordinary profit fell 15.1%. Performance against the stable revenue growth target deteriorated for the full year as well. - FY2017-Q3WorsenedAnnual report
「Amid this operating environment, we focused on expanding sales of high-value-added products that contribute to labor savings in blood collection and urine collection operations at medical facilities, including the fully automated urine aliquoting system UA・ROBO-2000RFID, the RFID blood transfusion management and verification system, and the RFID urine specimen management system, while steadily capturing replacement demand from existing users through BC・ROBO-8000RFID, our main blood collection tube preparation equipment model. However, due to the impact of a year-on-year decline in replacement projects for our main blood collection tube preparation equipment, revenue for the cumulative third quarter was ¥5,586.772 million, down 7.7% year on year.」
While measures to expand sales are continuing, cumulative third-quarter revenue declined 7.7% year on year due to a decrease in replacement projects for the main product. Operating profit fell 33.4% and ordinary profit fell 33.5%. Performance against the stable-growth target has deteriorated. - FY2017-Q2WorsenedAnnual report
「Revenue for the cumulative second quarter was ¥3,765.146 million, down 4.6% year on year.」
Revenue declined 4.6% year on year, while ordinary profit was ¥335.027 million, down 57.9%. Performance for the first half has deteriorated against the target of stable revenue growth. - FY2017-Q1WorsenedAnnual report
「However, due in part to a year-on-year decline in replacement projects for the blood collection tube preparation equipment, our revenue for the cumulative first quarter was ¥1,743.675 million, down 11.0% year on year.」
No change to the existing growth targets was stated, but revenue in FY2017-Q1 declined 11.0% year on year, while operating profit and ordinary profit each fell by around 35%. - FY2016First statedAnnual report
「We are working to achieve stable annual revenue growth of 12.5%–15.0% from the perspective of expanding the scale of our business, and a 20% ordinary profit margin on revenue from the perspective of securing profitability, in order to ensure business continuity and stable dividends for shareholders by continuously conducting R&D into new products offering new value and supplying products that meet market needs.」
The company has set annual revenue growth of 12.5%–15.0% and a 20% ordinary profit margin on revenue as management targets, with new-product R&D and responding to market needs as its means of achieving them.